BR112022007996A2 - Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida - Google Patents

Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida

Info

Publication number
BR112022007996A2
BR112022007996A2 BR112022007996A BR112022007996A BR112022007996A2 BR 112022007996 A2 BR112022007996 A2 BR 112022007996A2 BR 112022007996 A BR112022007996 A BR 112022007996A BR 112022007996 A BR112022007996 A BR 112022007996A BR 112022007996 A2 BR112022007996 A2 BR 112022007996A2
Authority
BR
Brazil
Prior art keywords
treatment
oxoisoindolin
biomarkers
chlorophenyl
methyl
Prior art date
Application number
BR112022007996A
Other languages
English (en)
Inventor
Lu Gang
Surka Christine
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112022007996A2 publication Critical patent/BR112022007996A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE BIOMARCADORES PARA PREVER A SENSIBILIDADE CLÍNICA A 2-(4-CLOROFENIL)-N-((2-(2,6-DIOXOPI- PERIDINA-3-IL)-1-OXOISOINDOLIN-5-IL)METIL)-2,2-DIFLUOROA- CETAMIDA. A presente invenção refere-se a um método para identificar um indivíduo que tem câncer sendo provável que seja responsivo a um tratamento compreendendo um composto ou prever a capacidade de resposta de um indivíduo que tem ou suspeito de ter câncer a um tratamento que compreende o composto, compreendendo: fornecer uma amostra do indivíduo; medir o nível de expressão de gene de um ou mais genes na amostra; e identificar o indivíduo como sendo provável que seja responsivo ao tratamento compreendendo o composto se o nível de expressão do gene for diferente de um nível de referência, e em que o gene é um gene envolvido na sinalização de mTOR ou o gene é ILF2 ou ILF3.
BR112022007996A 2019-10-28 2020-10-27 Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida BR112022007996A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926878P 2019-10-28 2019-10-28
PCT/US2020/057486 WO2021086830A1 (en) 2019-10-28 2020-10-27 Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Publications (1)

Publication Number Publication Date
BR112022007996A2 true BR112022007996A2 (pt) 2022-07-05

Family

ID=75716242

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007996A BR112022007996A2 (pt) 2019-10-28 2020-10-27 Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida

Country Status (11)

Country Link
US (1) US20220389515A1 (pt)
EP (1) EP4051275A4 (pt)
JP (1) JP2023500482A (pt)
KR (1) KR20220107182A (pt)
CN (1) CN114845716A (pt)
AU (1) AU2020376782A1 (pt)
BR (1) BR112022007996A2 (pt)
CA (1) CA3156232A1 (pt)
IL (1) IL292582A (pt)
MX (1) MX2022005159A (pt)
WO (1) WO2021086830A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN113046357B (zh) * 2021-01-25 2023-05-16 柳州市柳铁中心医院 一种乐伐替尼耐药基因dusp9、其筛选方法及应用
CN114703191A (zh) * 2022-04-19 2022-07-05 华南农业大学 基于crsipr技术构建rictor基因敲除细胞株的方法及其应用
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024192164A1 (en) * 2023-03-13 2024-09-19 The Johns Hopkins University Nonsense mediated decay inhibitor compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010125566A2 (en) * 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
WO2017027672A1 (en) * 2015-08-12 2017-02-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017120446A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
RS64029B1 (sr) * 2017-06-30 2023-03-31 Celgene Corp Kompozicije i postupci za upotrebu 2-(4-hlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoracetamida

Also Published As

Publication number Publication date
CN114845716A (zh) 2022-08-02
IL292582A (en) 2022-06-01
EP4051275A1 (en) 2022-09-07
WO2021086830A1 (en) 2021-05-06
MX2022005159A (es) 2022-06-08
US20220389515A1 (en) 2022-12-08
AU2020376782A1 (en) 2022-05-26
JP2023500482A (ja) 2023-01-06
KR20220107182A (ko) 2022-08-02
EP4051275A4 (en) 2024-02-07
CA3156232A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
BR112022007996A2 (pt) Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
Xu et al. Association between serum concentrations of perfluoroalkyl substances (PFAS) and expression of serum microRNAs in a cohort highly exposed to PFAS from drinking water
BR112014007214A2 (pt) predição de evento de risco cardiovascular e utilização do mesmo
Fredsøe et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine
Kwong et al. Quantification of circulating Epstein–Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance
Field et al. Recent developments in prognostic and predictive testing in uveal melanoma
Klein et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
BR112016004963A2 (pt) biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença
BR112013003391B8 (pt) Método para diagnosticar câncer pancreático em um indivíduo
Zhang et al. Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma
Abu-Amero et al. Detection of mitochondrial respiratory dysfunction in circulating lymphocytes using resazurin
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
Cho Molecular diagnostics for monitoring and predicting therapeutic effect in cancer
BR112013000869A2 (pt) método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
Huang et al. Association between polyfluoroalkyl chemical concentrations and leucocyte telomere length in US adults
Waterhouse et al. Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation
BR112017014097A2 (pt) tira de teste e sistema e método para medir a concentração de glicose em amostra de sangue
Davidson et al. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
BR112022019764A2 (pt) Ensaios para detecção de sars-cov-2
Polemi et al. Identifying the link between chemical exposures and breast cancer in African American women via integrated in vitro and exposure biomarker data
Litvinov et al. The role of AHI 1 and CDKN 1C in cutaneous T‐cell lymphoma progression
Allione et al. The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer
Slyskova et al. Functional evaluation of DNA repair in human biopsies and their relation to other cellular biomarkers

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]